Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.

Conclusions- SCH-28, a synthetic small-molecular and nonanticoagulant heparin analog, inhibits thrombin-induced PAR4 activation by interfering with thrombin exosite II, a mechanism of action distinct from other PAR4 inhibitors that target the receptor. The characteristics of SCH-28 provide a new strategy for targeting PAR4 with the potential for the treatment of arterial thrombosis.
PMID: 30727756 [PubMed - as supplied by publisher]

Source: Arteriosclerosis, Thrombosis and Vascular Biology - February 7, 2019 Category: Cardiology Authors: Lin YC, Ko YC, Hung SC, Lin YT, Lee JH, Tsai JY, Kung PH, Tsai MC, Chen YF, Wu CC Tags: Arterioscler Thromb Vasc Biol Source Type: research